Login to Your Account

Washington Roundup

Avandia Backtrack Raises a Number of Regulatory Questions

By Mari Serebrov
Washington Editor

Wednesday, November 27, 2013
With the FDA backpedaling on a decision it made three years ago to severely limit the use of Glaxosmithkline plc’s (GSK) Avandia and other diabetes drugs containing rosiglitazone, the damage resulting from that decision is calling into question the need for massive cardiovascular outcome trials (CVOTs) for diabetes drugs and the future regulatory role of meta-analysis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription